Latest news with #TNF-alpha
Yahoo
01-07-2025
- Business
- Yahoo
Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)
REYKJAVIK, Iceland and LONDON, July 01, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited ('Advanz Pharma'), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the companies have entered into a supply and commercialization agreement for AVT10, Alvotech's biosimilar candidate to Cimzia® (certolizumab pegol). 'Our biosimilar candidate is the only one referencing Cimzia® that is under development globally and the reference product has carved out significant market share as treatment for chronic rheumatic diseases, especially for women of childbearing age. I'm very pleased to add it to our expanding commercial partnership with Advanz Pharma,' said Róbert Wessman, Chairman and CEO of Alvotech. 'This agreement further strengthens our strategic partnership with Alvotech and supports our goal to expand access to high-quality biologics for patients in Europe. A proposed biosimilar to Cimzia® is a valuable addition to our sizable biosimilars pipeline,' said Steffen Wagner, CEO of Advanz pegol is a TNF-alpha inhibitor indicated for a variety of inflammatory diseases. Worldwide sales of Cimzia® in 2024 were US$2.3 billion [1].Alvotech and Advanz Pharma have previously entered into partnership agreements for biosimilar candidates to more than ten reference biologics. The companies expect to launch their first biosimilars in Europe in Q4 2025. Use of trademarksCimzia® is a registered trademark of UCB Pharma S.A. Sources[1] Global Data About AlvotechAlvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech's current pipeline includes eight disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech's commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit None of the information on the Alvotech website shall be deemed part of this press release. About Advanz PharmaPartner of choice in specialty, hospital, and rare disease medicines. Advanz Pharma is a global pharmaceutical company with the purpose to improve patients' lives by providing and enhancing the specialty, hospital, and rare disease medicines they depend on. Our headquarters are in London, UK. We have commercial sales in more than 90 countries globally and have a direct commercial presence in more than 20 countries, including key countries in Europe, the US, Canada, and Australia, a Centre of Excellence in Mumbai, India, as well as an established global distribution and commercialization partner network. Advanz Pharma's product portfolio and pipeline comprises innovative medicines, biosimilars & specialty generics, and originator brands. Our products cover a broad range of therapeutic areas, including hepatology, rheumatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and, more broadly, rare disease medicines. Our ambition is to be a partner of choice for the commercialization of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia. In line with our ambition, we are partnering with biopharma and development companies to bring medicines to patients. We can only achieve this due to our dedicated and highly qualified employees, acting in line with our company values of entrepreneurship, speed, and integrity. Forward Looking StatementsCertain statements in this communication may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example, Alvotech's expectations regarding its ability to satisfy conditions precedent to close the transaction and draw down the loan, to comply with the covenants of the Facility and to exercise its rights under the facility, the expected use of proceeds from the Facility, potential future financings or strategic transactions, Alvotech's competitive advantages, business prospects and opportunities including product launches, pipeline product development, revenue and diversification, future plans and intentions, results, level of activities, performance, goals or achievements or other future events, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, and market launches. In some cases, you can identify forward-looking statements by terminology such as 'may', 'should', 'expect', 'intend', 'will', 'estimate', 'anticipate', 'believe', 'predict', 'potential', 'aim' or 'continue', or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech's control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the ability to raise substantial additional funding, which may not be available on acceptable terms or at all; (2) the ability to maintain stock exchange listing standards; (3) changes in applicable laws or regulations; (4) the possibility that Alvotech may be adversely affected by other economic, business, and/or competitive factors; (5) Alvotech's estimates of revenue, expenses and profitability; (6) Alvotech's ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (7) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (8) the ability of Alvotech or its partners to gain approval from regulators for planned clinical studies, study plans or sites; (9) the ability of Alvotech's partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (10) Alvotech's ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (11) the success of Alvotech's current and future collaborations, joint ventures, partnerships or licensing arrangements; (12) Alvotech's ability, and that of its commercial partners, to execute their commercialization strategy for approved products; (13) Alvotech's ability to manufacture sufficient commercial supply of its approved products; (14) the outcome of ongoing and future litigation regarding Alvotech's products and product candidates; (15) the impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, conflicts in Ukraine, the Middle East and other global geopolitical tension, on the Company's business, financial position, strategy and anticipated milestones; (16) Alvotech's ability to meet the conditions precedent to close Facility and comply with the covenants of the Facility and (17) other risks and uncertainties set forth in the sections entitled 'Risk Factors' and 'Cautionary Note Regarding Forward-Looking Statements' in documents that Alvotech may from time to time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed. The recipient agrees that it shall not seek to sue or otherwise hold Alvotech or any of its directors, officers, employees, affiliates, agents, advisors, or representatives liable in any respect for the provision of this communication, the information contained in this communication, or the omission of any information from this communication. Advanz Pharma Forward Looking StatementsCertain statements in this press release are forward-looking statements. These statements may be identified by words such as 'anticipate', "expectation", "belief', "estimate", "plan", "target', 'project', 'will', 'may', 'should' or "forecast" and similar expressions, or by their context. Although Advanz Pharma believes that these assumptions were reasonable when made, by their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions affecting the industry, intense competition in the markets in which Advanz Pharma operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting Advanz Pharma's markets, and other factors beyond the control of Advanz Pharma. Neither Advanz Pharma nor any of its directors, officers, employees, advisors, or any other person is under any obligation to update or keep current the information contained in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this press release. Statements contained in this press release regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. No obligation is assumed to update any forward-looking statements. The information contained in this press release is provided as at the date of this document and is subject to change without notice. MEDIA CONTACTSAlvotech Global Communications and Investor RelationsBenedikt Advanz Pharma Global Corporate CommunicationsCourtney
India.com
25-06-2025
- Health
- India.com
The Silent Killer: What Really Happens If Endometriosis Is Left Untreated
Many still mistake endometriosis for 'bad period cramps.' But what starts as subtle pain can evolve into a dangerous, life-altering disease if left unchecked. Endometriosis doesn't just disrupt your cycle, it can damage organs, steal fertility, and affect your mental health for life. Dr Smeet Patel, Endometriosis Specialist at Mayflower Women's Hospital, Ahmedabad, reveals why early diagnosis and real treatment, not just hormonal suppression, are crucial. The Progressive Nature of Endometriosis "Endometriosis is not just a menstrual nuisance, it's a progressive, invasive disease," says Dr. Smeet Patel. It begins with mild discomfort and period pain but can quickly escalate into persistent pelvic and back pain, painful sex, neuropathic flares, and widespread symptoms that go well beyond menstruation. It spreads silently, forming scar tissue (adhesions) that fuses organs together, sometimes pulling ovaries toward the pelvic wall or tethering the uterus to the rectum. Lesions aren't confined to reproductive organs; they may affect the bowel, bladder, ureters, and even reach as far as the diaphragm. A Web of Symptoms You Can't Ignore The symptoms often reflect the disease's invasive reach, painful urination (dysuria), painful bowel movements (dyschezia), and painful sex (dyspareunia). But the pain is not 'just in your head.' Endometriosis rewires your nervous system. "The chronic inflammation causes central sensitisation," Dr. Patel explains. "This means your nerves become hypersensitive. It's neurological, not psychological." Left untreated, this hypersensitivity leads to intense, daily suffering. Years of Silent Progression and Misdiagnosis One of the most chilling aspects of endometriosis? It can slowly destroy your body for years before anyone realizes. "The average diagnosis takes 7 to 10 years," Dr. Patel says. During this time, irreversible fertility damage may occur—like blocked fallopian tubes or ovarian endometriomas, often discovered only during infertility evaluations. Deep lesions can go unnoticed until they cause life-threatening complications—bowel obstructions, kidney swelling, and even cyclical lung or chest pain if they reach the diaphragm or lungs. Treatment That Doesn't Treat the Root Cause Hormonal therapies like birth control pills or GnRH agonists may ease symptoms, but they're not a cure. Dr. Patel warns, "They mask symptoms, allowing the disease to progress undetected. Long-term use can even cause bone loss and severe mood disorders." Surgery, too, can backfire if not done correctly. 'Ablation-only' surgeries that burn surface lesions often cause more scar tissue and worsen the pain. The gold standard is complete laparoscopic excision by a specialist, but few women worldwide can access this care. Beyond the Pelvis: Systemic Health Risks Endometriosis is not just a reproductive disorder. It's a whole-body inflammatory condition. Chronic inflammation increases levels of cytokines (IL-1β, IL-6, TNF-alpha), which are linked to autoimmune diseases and even heart disease. Worse still, long-standing cases have been associated with increased risk of certain ovarian cancers, particularly clear cell and endometrioid subtypes. The Psychological Toll: Trauma That's Often Overlooked Living with chronic pain for years, being dismissed by doctors, and facing delays in treatment takes a serious emotional toll. 'Many patients develop anxiety, depression, and even PTSD,' Dr. Patel says. "The trauma of not being believed is real and lasting." Women frequently report being gaslighted by healthcare providers, told it's 'normal,' or advised to 'just take a painkiller.' These dismissals create lasting mistrust in the medical system. Why Early Diagnosis Is Everything Hormonal suppression isn't a cure, it's a temporary mask. By the time symptoms become unbearable, the disease may have already done lasting damage. That's why it's crucial to listen to patients early, take their pain seriously, and pursue proper diagnostics. Final Word: Don't Ignore the Early Signs If you, or someone you love, suffers from severe menstrual pain, chronic pelvic aches, or unusual digestive or urinary symptoms, don't wait. Endometriosis doesn't slow down. Left untreated, it can impact every aspect of life: fertility, organ function, and mental well-being. Early diagnosis and proper excision surgery can drastically change outcomes. Believe women. Advocate for better care. Because when it comes to endometriosis, ignorance isn't just harmful, it can be deadly.
Saba Yemen
26-05-2025
- Health
- Saba Yemen
Study: Reveals How Viral Infection Turns Your Joints into Source of Chronic Pain
Washington - (Saba): A recent scientific study has revealed that the mysterious mechanism by which the chikungunya virus causes chronic joint pain closely resembles autoimmune diseases, such as rheumatoid arthritis. Although most cases resolve spontaneously within one to two weeks, approximately 30-40% of patients may suffer from chronic joint pain that lasts for months or even years, with some potentially developing rheumatoid-like arthritis. Chikungunya virus is the virus that causes chikungunya disease (CHIKV), an acute infection transmitted to humans through the bites of Aedes aegypti and Aedes albopictus mosquitoes, the two species responsible for transmitting dengue fever. The disease is characterized by the sudden onset of symptoms, including a high fever and severe joint pain, particularly in the extremities, accompanied by a rash, muscle pain, and headache. The results of a new study, published in the journal Cell Reports Medicine, pave the way for a deeper understanding of the complex relationship between this viral infection and autoimmune diseases. The study, conducted by a team from the La Jolla Institute for Immunology, analyzed blood samples from patients exposed to chikungunya in Colombia. The researchers tracked the behavior of immune cells, particularly CD4+ helper T cells, in combating the virus. What surprised the research team was the discovery that these cells—and not CD8+ killer T cells, as expected—led the fight against the virus and persisted in the body for years after the infection cleared. The data show that 87% of patients retained these cells in their blood six years after the initial infection, while killer cells were detected in only 13% of cases. Even more striking is that these helper cells switch to a "monofunctional" pattern, essentially secreting the inflammatory molecule TNF-alpha continuously, even after the virus has been eliminated. This abnormal behavior of immune cells closely resembles what we see in autoimmune diseases, where the immune system attacks healthy body tissue. "We would normally expect to see this pattern of immune response in autoimmune diseases such as rheumatoid arthritis, not in viral infections," says Dr. Daniela Weisskopf, lead researcher of the study. This discovery provides a compelling scientific explanation for why many patients suffer from chronic joint pain that can persist for years after contracting the virus. These findings are particularly important in light of the widespread spread of the virus in more than 110 countries, and the similarity of its symptoms to other conditions such as "long COVID" and the long-term effects of dengue fever. They also open the door to developing more precise treatments that target these specific inflammatory pathways, and perhaps the use of TNF-alpha inhibitors, which have proven effective in some autoimmune diseases. Whatsapp Telegram Email Print more of (International)
Time of India
12-05-2025
- Health
- Time of India
Doctors say THIS mineral reduces inflammation
You must have heard the word inflammation a lot in the past few years, and how it can cause a host of health issues, including weight gain, heart disease, arthiritis etc. But is there a way to curtail it? Let's find out more: What exactly is inflammation? Inflammation is the body's natural response to injury or infection. While short-term inflammation helps heal wounds and is not a cause of concern (say like a fever), however if chronic, inflammation can cause a host of health issues, as mentioned earlier. However, do you know that there is one mineral that can reduce inflammation naturally? And that mineral is magnesium . Let's take a look how... What is magnesium? Magnesium is a key mineral found in foods like nuts, seeds, leafy greens, and whole grains. Magnesium helps regulate the immune system and inflammation. When magnesium levels are low, the body tends to have more inflammation, which can lead to health issues. How does it reduce inflammation? One way magnesium reduces inflammation is by lowering the levels of proteins called cytokines. In layman language, cytokines are like messengers that tell the immune system to start or stop inflammation. Some cytokines cause inflammation, and when they are too high, it leads to chronic inflammation . Doctors say that magnesium decreases the production of inflammatory cytokines such as TNF-alpha and IL-6. It does this by blocking a key pathway inside cells called NF-κB (Nuclear Factor kappa B). NF-κB controls the activity of many genes involved in inflammation. Magnesium stops NF-κB from becoming too active, which in turn calms the immune response. Natural Calcium Blocker Magnesium also helps reduce inflammation by balancing calcium levels in the body. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Invest $200 in Amazon without buying stocks to earn a second salary Marketsall Sign Up Undo While Calcium is needed for many body functions, too many of calcium cells can cause cause inflammation and damage. Magnesium acts like a natural calcium blocker, preventing excess calcium from entering cells and triggering inflammation. Lowers inflammatory markers Inflammatory markers like C-reactive protein (CRP) and fibrinogen are substances in the blood that increase during inflammation. Research shows that magnesium supplements can significantly reduce these markers, indicating a lower level of inflammation in the body. Magnesium helps the immune system Magnesium supports the immune system by regulating how it responds to threats. Low magnesium levels can cause an overactive immune response, leading to high inflammation. By increasing magnesium levels, the immune system becomes better balanced, reducing the risk of chronic inflammation and related illnesses. Now, let's take a look at foods that are high in magnesium: Leafy green vegetables Nuts and seeds Legumes Whole grains Fruits Fish Dark chocolate Get the latest lifestyle updates on Times of India, along with Mother's Day wishes , messages , and quotes !
Associated Press
08-05-2025
- Business
- Associated Press
TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists
BALTIMORE--(BUSINESS WIRE)--May 8, 2025-- TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ('TNF' or the 'Company'), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, and Renova Health, a company committed to focusing on outpatient care to minimize costs, impact and the need for hospitalization, today announced positive results from the first stage of a general practice population study focusing on patients receiving GLP-1 agonists. The study series is expected to evaluate the impact of the Company's novel oral TNF-alpha (TNF-α) inhibitor drug, isomyosamine, in preserving lean muscle mass during and after GLP-1 treatment for weight loss and chronic weight management in patients who are a) on GLP-1 agonists, b) candidates for treatment with GLP-1 agonists, or c) probably not suitable for treatment with weight loss therapy. In coordination with Renova Health, the purpose of this first stage was to analyze 30,000 patients already under the care of primary care physicians and identify convergences between the use of GLP-1 agonists and chronic disorders linked with increased risk of inflammation. The data were parsed into three cohorts depending on prespecified criteria. TNF plans to use these data to optimize appropriate patient recruitment and accelerate isomyosamine drug development. TNF's President and Chief Medical Officer, Mitchell Glass, M.D., commented, 'Our goal for our GLP-1 study series is to identify patients who are taking GLP-1 agonists to test whether isomyosamine can decrease inflammation and prevent or ameliorate the risk of adverse outcomes such as muscle wasting in patients who have baseline TNF-derived inflammatory signals. In our initial review of the data, we have already noted that sarcopenia and frailty are both underreported, which we believe provides evidence that at-risk populations could suffer adverse events from GLP-1 treatment without adequate surveillance to detect and treat drug-induced muscle wasting.' 'The prevalence of certain disorders such as sarcopenia were well below the Centers for Disease Control and Prevention's estimates in community dwelling adults,' said Dave Jacobs, Chief Executive Officer of Renova Health. 'Identifying patients in the community who are at increased risk of fall may enable us to use non-invasive monitoring to identify these patients earlier and more accurately and to provide support. We believe early and ongoing evaluation of sarcopenic and frail patients could enable us to impact quality of life in thousands of patients once identified and followed with straightforward and validated tests of balance and cognition.' About Renova Health Renova Health partners with large clinic practices, hospital systems, and accountable care organizations to help deliver better patient outcomes at a lower cost. The key to Renova Health's success is its highly skilled, caring, and passionate Personal Health Advocates that create and nurture a personal, trusting relationship with patients that helps to uncover deeper insights and ultimately leads to superior healthcare outcomes. For more information, visit About Isomyosamine Isomyosamine is a novel plant alkaloid small molecule shown to regulate the immuno-metabolic system through the modulation of numerous pro-inflammatory cytokines including TNF-alpha (TNF-α), an immune cell signaling protein and inflammatory cytokine responsible for inducing and maintaining the inflammatory process. TNF-α is located upstream of a cascade of molecular signals that induces inflammation and helps activate the process of aging. Many in vivo and in vitro studies have shown that TNF-α plays a causative role in the pathogenesis of various age-related diseases. About TNF Pharmaceuticals, Inc. TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. Isomyosamine is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. Isomyosamine is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit Cautionary Statement Regarding Forward-Looking Statements This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'may,' 'plan,' 'will,' 'would'' and other similar expressions are intended to identify these forward-looking statements. Examples of such statements include, but are not limited to, statements regarding the Company's goals and expectations related to the Company's partnership with Renova Health. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the Company's ability to maintain compliance with the Nasdaq Stock Market's listing standards; the timing of, and the Company's ability to, obtain and maintain regulatory approvals for clinical trials of the Company's pharmaceutical candidates; the timing and results of the Company's planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company's ability to retain and attract senior management and other key employees; the Company's ability to quickly and effectively respond to new technological developments; and the Company's ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company's proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed by the Company on April 11, 2025, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise. View source version on CONTACT: Investor Contact: Robert Schatz (646) 421-9523 [email protected] KEYWORD: UNITED STATES NORTH AMERICA MARYLAND INDUSTRY KEYWORD: RESEARCH TECHNOLOGY CLINICAL TRIALS HEALTH TECHNOLOGY BIOTECHNOLOGY PHARMACEUTICAL HEALTH SCIENCE ARTIFICIAL INTELLIGENCE OTHER SCIENCE SOURCE: TNF Pharmaceuticals, Inc. Copyright Business Wire 2025. PUB: 05/08/2025 09:20 AM/DISC: 05/08/2025 09:19 AM
